Common header menu

Breadcrumb

Astellas Enters a New Collaborative Research Agreement with AIST to Discover Anti-protozoan Parasite Drugs for the Treatment of Chagas' disease, one of Neglected Tropical Diseases

Important Notice

This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site.

Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.

I Agree

Thank you for visiting the Astellas Pharma Inc. Website.
You will enter external sites beyond here.(This link opens in a new window)

Tokyo, April 1, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") today announced that it has signed a new collaborative research agreement with the National Institute of Advanced Industrial Science and Technology (Headquartered in Tsukuba, President: Ryoji Chubachi, "AIST") to discover anti-protozoan parasite drugs for the treatment of Chagas’ disease, one of neglected tropical diseases1) (“NTDs”).

Astellas is committed to improving “Access to Health2)” in the world. As part of the initiative, Astellas has been collaborating with five research institutions in Japan as well as with an international non-profit organization (“NPO”) since 2012 to discover new drugs for the treatment of NTDs caused by protozoan parasites belonging to trypanosomatidae (i.e., leishmaniasis3), Chagas’ disease4), and African trypanosomiasis5)) that represent significant unmet medical needs (“existing collaborative research”).

Under this new agreement, Astellas and AIST will conduct collaborative research to discover new drugs for the treatment of Chagas’ disease, using genome editing technology6) and a high throughput activity assay7) for Trypanosoma cruzi (the cause of the disease) that have been obtained through the existing collaborative research. As Chagas’ disease is one of the most prevalent NTDs and no specific drugs are available for the disease, the discovery of new effective drugs will help to address a critical unmet need.

Astellas and AIST will work collaboratively to validate whether genes crucial for the survival of Trypanosoma cruzi can be pinpointed in a short period of time using gene editing technology. Astellas will mainly be responsible for selecting appropriate genes to be verified, and AIST will lead the gene editing process. After the validation in this collaborative research initiative, the formation of AIST-driven research consortium, in which multiple research institutions will participate to conduct extensive genome editing studies and pursue discovery of new drugs for the treatment of Chagas’ disease in a larger framework is planned. Astellas is undergoing a review process to further assess the possibility about joining the consortium.

The existing collaborative research was terminated at the end of the current agreements, as the collaborative research failed in identifying potential compounds with appropriate profiles for the development of anti-protozoan parasite drugs due to the lack of data on target genes critical for the survival of Trypanosoma cruzi. Collaborative drug discovery research on anti-dengue virus with two research institutions in Japan has also been terminated, as the research failed to identify promising compounds.

Astellas will continue to be committed to enhancing Access to Health through this new collaborative research for the discovery of new drugs for patients suffering from Chagas’ disease in the world.